BR112014018732A8 - Composições imunogênicas contra campylobacter e usos das mesmas - Google Patents

Composições imunogênicas contra campylobacter e usos das mesmas

Info

Publication number
BR112014018732A8
BR112014018732A8 BR112014018732A BR112014018732A BR112014018732A8 BR 112014018732 A8 BR112014018732 A8 BR 112014018732A8 BR 112014018732 A BR112014018732 A BR 112014018732A BR 112014018732 A BR112014018732 A BR 112014018732A BR 112014018732 A8 BR112014018732 A8 BR 112014018732A8
Authority
BR
Brazil
Prior art keywords
immunogenic compositions
compositions against
against campylobacter
campylobacter
immunogenic
Prior art date
Application number
BR112014018732A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112014018732A2 (cg-RX-API-DMAC10.html
Inventor
A Joens Lynn
Law Bibiana
Armstrong Alexandra
Original Assignee
Univ Arizona
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Arizona filed Critical Univ Arizona
Publication of BR112014018732A2 publication Critical patent/BR112014018732A2/pt
Publication of BR112014018732A8 publication Critical patent/BR112014018732A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/205—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Campylobacter (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/105—Delta proteobacteriales, e.g. Lawsonia; Epsilon proteobacteriales, e.g. campylobacter, helicobacter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
BR112014018732A 2012-02-01 2013-02-01 Composições imunogênicas contra campylobacter e usos das mesmas BR112014018732A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261632888P 2012-02-01 2012-02-01
US201261689078P 2012-05-29 2012-05-29
PCT/US2013/024332 WO2013116639A1 (en) 2012-02-01 2013-02-01 Campylobacter immunogenic compositions and uses thereof

Publications (2)

Publication Number Publication Date
BR112014018732A2 BR112014018732A2 (cg-RX-API-DMAC10.html) 2017-06-20
BR112014018732A8 true BR112014018732A8 (pt) 2017-07-11

Family

ID=47682080

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014018732A BR112014018732A8 (pt) 2012-02-01 2013-02-01 Composições imunogênicas contra campylobacter e usos das mesmas

Country Status (5)

Country Link
US (4) US9328148B2 (cg-RX-API-DMAC10.html)
EP (1) EP2809347A1 (cg-RX-API-DMAC10.html)
CN (1) CN104159601B (cg-RX-API-DMAC10.html)
BR (1) BR112014018732A8 (cg-RX-API-DMAC10.html)
WO (1) WO2013116639A1 (cg-RX-API-DMAC10.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080124355A1 (en) 2006-09-22 2008-05-29 David Gordon Bermudes Live bacterial vaccines for viral infection prophylaxis or treatment
EP2766388A1 (en) * 2011-10-12 2014-08-20 Møller, Niels Iversen Peptides derived from campylobacter jejuni and their use in vaccination
CN104159601B (zh) 2012-02-01 2017-05-24 代表亚利桑那大学的亚利桑那董事会 弯曲杆菌属免疫原性组合物及其用途
US10376571B2 (en) 2013-03-15 2019-08-13 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses to enteric pathogens
US9470684B2 (en) * 2013-08-06 2016-10-18 Techlab, Inc. Outer membrane protein 18 as a diagnostic marker for campylobacter
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
CN110520153B (zh) 2017-01-27 2024-04-02 佛罗里达大学研究基金公司 在禽类中控制肠道沙门氏菌和减少弯曲杆菌的食品安全疫苗
CN110041109A (zh) * 2019-04-22 2019-07-23 刘坚 一种猪粪源生物肥的制备方法
CN111041017B (zh) * 2019-12-31 2020-10-16 潍坊麦卡阿吉生物科技有限公司 一种壳聚糖酶突变体及其应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5436146A (en) 1989-09-07 1995-07-25 The Trustees Of Princeton University Helper-free stocks of recombinant adeno-associated virus vectors
US5562909A (en) 1993-07-12 1996-10-08 Massachusetts Institute Of Technology Phosphazene polyelectrolytes as immunoadjuvants
US5571531A (en) 1994-05-18 1996-11-05 Mcmaster University Microparticle delivery system with a functionalized silicone bonded to the matrix
US20020168342A1 (en) 1994-11-03 2002-11-14 Cell Genesys, Inc. Novel adenoviral vectors, packaging cell lines, recombinant adenoviruses and methods
US6093570A (en) 1995-06-07 2000-07-25 The University Of North Carolina At Chapel Hill Helper virus-free AAV production
US6040183A (en) 1995-06-07 2000-03-21 University Of North Carloina At Chapel Hill Helper virus-free AAV production
EP1007637B1 (en) 1997-04-14 2004-06-30 Cell Genesys, Inc. Methods for increasing the efficiency of recombinant aav product
US20010038844A1 (en) 1998-05-04 2001-11-08 Irving Nachamkin Methods and vaccines for protection against campylobacter infections
EP2380440B1 (en) 2002-04-15 2016-03-09 Washington University Regulated attenuation of live vaccines to enhance cross protective immunogenicity
ES2358804T3 (es) 2003-11-21 2011-05-13 Ace Biosciences A/S Polipéptidos de campylobacter jejuni ubicados en superficie.
WO2008008092A2 (en) 2006-07-10 2008-01-17 The Arizona Board Of Regents On Behalf Of The University Of Arizona Campylobacter pilus protein, compositions and methods
CN104159601B (zh) * 2012-02-01 2017-05-24 代表亚利桑那大学的亚利桑那董事会 弯曲杆菌属免疫原性组合物及其用途

Also Published As

Publication number Publication date
BR112014018732A2 (cg-RX-API-DMAC10.html) 2017-06-20
WO2013116639A1 (en) 2013-08-08
EP2809347A1 (en) 2014-12-10
CN104159601A (zh) 2014-11-19
US11203618B2 (en) 2021-12-21
CN104159601B (zh) 2017-05-24
US20200317737A1 (en) 2020-10-08
US20190031725A1 (en) 2019-01-31
US20150030624A1 (en) 2015-01-29
US20160184422A1 (en) 2016-06-30
US10683330B2 (en) 2020-06-16
US10030054B2 (en) 2018-07-24
US9328148B2 (en) 2016-05-03

Similar Documents

Publication Publication Date Title
BR112012019757A2 (pt) composição imunogênica, e, método para induzir uma resposta imune a um polissacarídeo capsular
BR112019004785A2 (pt) variantes de alfa-glicosidase ácida e usos das mesmas
BR112018003745A2 (pt) composições que compreendem um composto de urolitina
BR112017002761A2 (pt) composições anti-metanogênicas e usos das mesmas
MX374547B (es) Método para mejorar las inmunoterapias especifícas en el tratamiento contra el cáncer.
BR112014028476A2 (pt) fragmento imunogênico de um polipeptídeo, polinucleotídeo isolado, composição farmacêutica imunogênica, métodos para tratar uma infecção, para gerar uma resposta imune em um sujeito, e para imunizar um sujeito
BR112016002199A2 (pt) Proteína anti-garp e usos da mesma
BR112015030514A2 (pt) Composições e métodos para conjugação de anticorpos ativáveis
MX2017004838A (es) Composiciones de interleucina-15 y usos de estas.
BR112016024357A2 (pt) composições de insulina de ação rápida
SMT201700182T1 (it) Composizioni di composti modificanti la risposta immunitaria lipidati, formulazioni e metodi
BR112019004783A2 (pt) variantes de alfa-glicosidase ácida e usos das mesmas
MX2016008448A (es) Conjugados de var2csa-farmaco.
BR112015018877A2 (pt) Método para preparar uma composição farmacêutica, e, composição farmacêutica imunogênica
BR112015015870A2 (pt) composição farmacêutica
MX2015000442A (es) Composiciones vacuna.
EP3142695A4 (en) Compositions and methods of enhancing immunogenicity of polysaccharide-protein conjugates
MX2015012833A (es) Composiciones antibioticas de ceftolozano.
BR112019003577A2 (pt) métodos de tratamento da semente e produtos resultantes
IL251120A0 (en) Immunogenic/therapeutic glycoside preparations and their uses
BR112017004197A2 (pt) composições de vacina contra doenças do vírus da dengue
BR112019011812A2 (pt) composições nutricionais contendo butirato e usos das mesmas
MX2017016401A (es) Composiciones inmunogenas.
BR112016010072A8 (pt) conjugado, composição farmacêutica, usos do conjugado ou da composição farmacêutica, e de polissacarídeo de vi fragmentado, e, método para a fabricação de um conjugado
BR112017026241A2 (pt) composições farmacêuticas e alimentícias para induzir a saciação e prolongar a saciedade em indivíduos que necessitem das mesmas

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements